194 related articles for article (PubMed ID: 21455987)
1. Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Kogias E; Osterberg N; Baumer B; Psarras N; Koentges C; Papazoglou A; Saavedra JE; Keefer LK; Weyerbrock A
Int J Cancer; 2012 Mar; 130(5):1184-94. PubMed ID: 21455987
[TBL] [Abstract][Full Text] [Related]
2. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.
Weidensteiner C; Reichardt W; Shami PJ; Saavedra JE; Keefer LK; Baumer B; Werres A; Jasinski R; Osterberg N; Weyerbrock A
Nitric Oxide; 2013 Apr; 30():17-25. PubMed ID: 23370169
[TBL] [Abstract][Full Text] [Related]
3. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.
Weyerbrock A; Osterberg N; Psarras N; Baumer B; Kogias E; Werres A; Bette S; Saavedra JE; Keefer LK; Papazoglou A
Neurosurgery; 2012 Feb; 70(2):497-510; discussion 510. PubMed ID: 21849924
[TBL] [Abstract][Full Text] [Related]
4. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug.
Findlay VJ; Townsend DM; Saavedra JE; Buzard GS; Citro ML; Keefer LK; Ji X; Tew KD
Mol Pharmacol; 2004 May; 65(5):1070-9. PubMed ID: 15102935
[TBL] [Abstract][Full Text] [Related]
5. A glutathione S-transferase pi-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins.
Townsend DM; Findlay VJ; Fazilev F; Ogle M; Fraser J; Saavedra JE; Ji X; Keefer LK; Tew KD
Mol Pharmacol; 2006 Feb; 69(2):501-8. PubMed ID: 16288082
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.
Kumar V; Hong SY; Maciag AE; Saavedra JE; Adamson DH; Prud'homme RK; Keefer LK; Chakrapani H
Mol Pharm; 2010 Feb; 7(1):291-8. PubMed ID: 20000791
[TBL] [Abstract][Full Text] [Related]
7. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Grossman R; Rudek MA; Brastianos H; Zadnik P; Brem H; Tyler B; Blakeley JO
Cancer Chemother Pharmacol; 2012 Jul; 70(1):129-39. PubMed ID: 22644796
[TBL] [Abstract][Full Text] [Related]
8. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Grossman R; Brastianos H; Blakeley JO; Mangraviti A; Lal B; Zadnik P; Hwang L; Wicks RT; Goodwin RC; Brem H; Tyler B
J Neurooncol; 2014 Jan; 116(1):59-65. PubMed ID: 24185441
[TBL] [Abstract][Full Text] [Related]
9. The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation.
Heckler M; Osterberg N; Guenzle J; Thiede-Stan NK; Reichardt W; Weidensteiner C; Saavedra JE; Weyerbrock A
Tumour Biol; 2017 Jun; 39(6):1010428317703922. PubMed ID: 28653883
[TBL] [Abstract][Full Text] [Related]
10. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
[TBL] [Abstract][Full Text] [Related]
11. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro.
Weyerbrock A; Baumer B; Papazoglou A
J Neurosurg; 2009 Jan; 110(1):128-36. PubMed ID: 18991497
[TBL] [Abstract][Full Text] [Related]
14. PABA/NO lead optimization: Improved targeting of cytotoxicity to glutathione S-transferase P1-overexpressing cancer cells.
Kim Y; Maciag AE; Cao Z; Deschamps JR; Saavedra JE; Keefer LK; Holland RJ
Bioorg Med Chem; 2015 Aug; 23(15):4980-4988. PubMed ID: 26043946
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound.
Chakrapani H; Wilde TC; Citro ML; Goodblatt MM; Keefer LK; Saavedra JE
Bioorg Med Chem; 2008 Mar; 16(5):2657-64. PubMed ID: 18060792
[TBL] [Abstract][Full Text] [Related]
16. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
D'Alessandro G; Grimaldi A; Chece G; Porzia A; Esposito V; Santoro A; Salvati M; Mainiero F; Ragozzino D; Di Angelantonio S; Wulff H; Catalano M; Limatola C
Oncotarget; 2016 May; 7(21):30781-96. PubMed ID: 27096953
[TBL] [Abstract][Full Text] [Related]
17. Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats TS
Cancer Biol Ther; 2009 Oct; 8(20):1924-33. PubMed ID: 19738431
[TBL] [Abstract][Full Text] [Related]
18. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Saito R; Bringas JR; Panner A; Tamas M; Pieper RO; Berger MS; Bankiewicz KS
Cancer Res; 2004 Oct; 64(19):6858-62. PubMed ID: 15466173
[TBL] [Abstract][Full Text] [Related]
19. Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas.
Weyerbrock A; Walbridge S; Pluta RM; Saavedra JE; Keefer LK; Oldfield EH
J Neurosurg; 2003 Oct; 99(4):728-37. PubMed ID: 14567609
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Lin CJ; Lee CC; Shih YL; Lin TY; Wang SH; Lin YF; Shih CM
Free Radic Biol Med; 2012 Jan; 52(2):377-91. PubMed ID: 22094224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
